Andrew John Phillips - 05 Jun 2025 Form 4 Insider Report for MoonLake Immunotherapeutics (MLTX)

Role: Director
Signature: /s/ Matthias Bodenstedt, Attorney-in-fact for Andrew John Phillips
Issuer symbol: MLTX
Transactions as of: 05 Jun 2025
Net transactions value: $0
Form type: 4
Filing time: 09 Jun 2025, 09:05:38 UTC
Previous filing: 30 May 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Phillips Andrew John	Director	C/O MOONLAKE IMMUNOTHERAPEUTICS, DORFSTRASSE 29, ZUG, SWITZERLAND	/s/ Matthias Bodenstedt, Attorney-in-fact for Andrew John Phillips	09 Jun 2025	0001921956

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MLTX	Option to Buy	Award	$0	+6,682		$0.000000	6,682	05 Jun 2025	Class A ordinary shares, par value $0.0001 per share	6,682	$48.83	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This option represents a right to purchase a total of 6,682 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 5, 2026 and (ii) the date of the Issuer's next annual general meeting of shareholders, subject to the Reporting Person's continued service to the Issuer.